Interesting that someone shows up on a board the day a company releases news of FDA approval on their first pipeline drug only to try to tear the company apart, why?
RGBP is a spinoff of BMSN it is true. It is also true that unlike BMSN, RGBP has employees and set out in 2015 setting goals and incentives for the scientists to achieve to bring value to company. 2015, unlike many years with BMSN, has had measurable acheivements and improvements, not the least of which is final FDA approval for a pretty much automatic Orphan Drug status treatment of HemaXellerate. HemaXellerate has advantage not only of orphan drug status and accelerated process, but the Phase I clinical trials only needs 10 patients and no blind testing. Therefore, they don't have to raise millions to engage in a Phase I clinical trial.
2015 has brought patents, outside partners (so I guess Dr. Kesari amongst others, who are working on RGBP's tab at approved national cancer institutes are all part of a scientific scam - NOT.) If RGBP had really followed ENTB and BMSN which were Koos employed only companies for the most part, there would be an argument for WB, but the fact that RGBP is working with outside legitimate companies and scientists with now multiple candidates and 1st FDA approval, it's pretty silly to claim it's all "a scam".
While I don't like Koos' practice of how he prices shares to outside investors and loans to himself - yes this is a problem, you can't bash FDA approval as scam. The only person discredited in doing so is the one claiming such a thing.
AIMO
